Live feed06:00:00·272dPRReleasevia QuantisnowPalvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved TherapiesByQuantisnow·Wall Street's wire, on your screen.PVLA· Palvella Therapeutics Inc.Health Care
